Drugs for the treatment of menopausal symptoms

Bibliography

• Davis SR, Dinatale I, Rivera-Woll L, Postmenopausal hormone therapy: from monkey glands to transdermal patches. J Endocrinol 2005;185(2):207-22
   Google Scholar
• Soules MR, Sherman S, Parrott E, Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4(4):267-72
   Google Scholar
• Soules MR, Sherman S, Parrott E, Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med 2001;10(9):843-8
   Google Scholar
• Freeman EW, Sammel MD, Lin H, Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007;110(2 Pt 1):230-40
   Google Scholar
• Bachmann GA. A new option for managing urogenital atrophy in postmenopausal women. Cont Obstet Gynecol 1997;42:13-28
   Google Scholar
• Eichling PS, Sahni J. Menopause related sleep disorders. J Clin Sleep Med 2005;1(3):291-300
   Google Scholar
• Writing Group, for Women's Health initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002(288):321-33
   Google Scholar
• Anasti JN, Kalantaridou SN, Kimzey LM, Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1998;91(1):12-5
   Google Scholar
• Luisetto G, Zangari M, Nardi A, Influence of aging and menopause in determining vertebral and distal forearm bone loss in adult healthy women. Bone Miner 1993;22(1):9-25
   Google Scholar
• Christiansen C, Bagger Y, Chetaille E, Varin C. Pulsed estrogen therapy prevents postmenopausal bone loss: a 2 year randomized placebo-controlled study. Proceeding of the 10th International Congress on the Menopause; Berlin, Germany; 2002. p. 87
   Google Scholar
• Maffei L, Murata Y, Rochera V, Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol. J Clin Endocrinol Metab 2004;89:61-70
   PubMed Web of Science ®Google Scholar
• Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas 2008;60:10-8
   PubMed Web of Science ®Google Scholar
• Sambrook PN, Seeman E, Phillips SR, Ebeling PR. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. 2002;176(S5):1-16
   Google Scholar
• Henry D, Robertson J, O'Connell D, Gillespie W. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 and 1995. Climacteric 1998;1:92-111
   PubMedGoogle Scholar
• Seeman E. Osteoporosis: trials and tribulations. 1997;103:74s-87s
   Google Scholar
• Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 Havard School of Public Health, Boston; 1996
   Google Scholar
• Yusuf S, Hawken S, Ounpuu S, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case controlled study. Lancet 2004;364:937-52
   PubMed Web of Science ®Google Scholar
• Leiberman EH, Gerhard M, Uehata A, Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Akishita M, Eto M, Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 1995;92:3431-5
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340(23):1801-11
   Google Scholar
• Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90
   PubMed Web of Science ®Google Scholar
• Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia postmenopausal women. N Eng J Med 1997;337(9):595-601
   Google Scholar
• The Writing Group for the PT. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208
   Google Scholar
• Lobo R, Bush T, Carr B, Pickar J. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors and carbohydrate metabolism. Fertil Steril 2001;76(1):13-24
   Google Scholar
• Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in post-menopausal women. Menopause 2000;7:395-401
   PubMed Web of Science ®Google Scholar
• O'Sullivan AJ, Crampton LJ, Freund J, Ho KKY. The route of estrogen replacement therapy confer divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 1998;102(5):1035-40
   Google Scholar
• O'Sullivan AJ, Ho K. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995(80):1783-8
   Google Scholar
• Davison SL, Davis SR. New markers for cardiovascular disease risk in women-impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88(6):2470-8
   Google Scholar
• Colditz GA, Willett WC, Stampfer MJ, Menopause and the risk of coronary heart disease in women. N Eng J Med 1987;316(18):1105-10
   Google Scholar
• Mack WJ, Slater CC, Xiang M, Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril 2004;82(2):391-7
   Google Scholar
• Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence in a random sample. BMJ 1995;311(7017):1401-5
   Google Scholar
• Lemieux S, Prud'homme D, Bouchard C, A single threshold value of waist girth identifies normal weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996;64(5):685-93
   Google Scholar
• Lee CG, Carr MC, Murdoch SJ, Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 2009;94(4):1104-10
   Google Scholar
• Franklin RM, Ploutz-Snyder L, Kanaley JA. Longitudinal changes in abdominal fat distribution with menopause. Metabolism 2009;58(3):311-15
   Google Scholar
• Bello N, Mosca L. Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis 2004;46(4):287-95
   Google Scholar
• Cust AE, Stocks T, Lukanova A, The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 2009;113(3):567-76
   Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20(1):42-51
   Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52(9):1766-77
   Google Scholar
• North American Menopause Society. Estrogen and progesogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 2008;15:584-602
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12
   PubMed Web of Science ®Google Scholar
• NIH-Pannel. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. Ann Intern Med 2005;142(12):1003-13
   Google Scholar
• Cardozo L, Bachmann GA, McClish D, Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second Report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92(4):722-7
   Google Scholar
• Hendrix SL, Cochrane BB, Nygaard IE, Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005;293(8):935
   PubMed Web of Science ®Google Scholar
• Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 2004;103(2):254-60
   Google Scholar
• Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 2001;142(11):4589-94
   Google Scholar
• Lobo R. Absorption and metabolic effects of different types of estrogens and progestogens. Obstet Gynecol Clin North Am 1987;14:143
   PubMed Web of Science ®Google Scholar
• Slater C, Hodis H, Mack W, Markedly elevated levels of estrone sulfate after long term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause 2001;8(3):200-3
   Google Scholar
• Dunn JF, Nisula BC, Rodboard D. Transport of steroid hormones. Binding of 21 endogenous steroids to both testosterone-binding globulin and cortico-steroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981;53:58
   PubMed Web of Science ®Google Scholar
• Nachtigall L, Raju U, Banerjee S, Serum estradiol binding profiles in postmenopausal women undergoing three common estrogen replacement therapies. Menopause 2000;7:243-50
   PubMed Web of Science ®Google Scholar
• Pasqualini JR, Chetrite G, Blacker C, Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996;81:1460-4
   PubMed Web of Science ®Google Scholar
• Raisz LG, Wiita B, Artis A, Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resoprtion in postmenopausal women. J Clin Endocrinol Metab 1996;81(1):37-43
   Google Scholar
• Stadberg E, Mattsson LA, Uvebrant M. 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 1996;23(1):31
   Google Scholar
• Hulley S, Grady D, Bush T, Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women.Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280(7):605-13
   Google Scholar
• Simon JA, Bouchard C, Waldbaum A, Low dose transdermal estrogen gel for treatment of symptomatic postmenoapusal women: a randomized controlled trail. Obstet Gynecol 2007;109(3):588-96
   PubMed Web of Science ®Google Scholar
• Scarabin P-Y, Oger E, Plu-Bureau G, Group EaTRS. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432
   PubMed Web of Science ®Google Scholar
• Society BoToTNAM. Position statement: management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17(1):25-54
   Google Scholar
• Cauley JA, Robbins J, Chen Z, Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290(13):1729-38
   Google Scholar
• Archer D, Gallagher J, Gass M, Recommendations for estrogen and progestogen use in peri-and postmenopausal women: october 2004 position statement of the North American Menopause Society. Menopause 2004;11(6 pt 1):583-4
   Google Scholar
• Beresford S, Weiss N, Voigt L, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-61
   PubMed Web of Science ®Google Scholar
• Pasqualini JR. Progestins: present and future. J Steroid Biochem Mol Biol 1996;59(5/6):357
   Google Scholar
• Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer 2009;126(2):483-9
   Google Scholar
• Collaborative Group on Hormonal Factors on Breast C. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047
   Google Scholar
• Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. MJA 2008;188(11):641-4
   Google Scholar
• Chlebowski Rea. Breast cancer after use of estrogen and progestin in postmenopausal women. NEJM 2009;360:573-87
   Google Scholar
• Sprague BL, Trentham-Dietz A, Burnside ES. Socioeconomic disparities in the decline in invasive breast cancer incidence. Breast Cancer Res Treat 2010. [Epub ahead of print]
   Google Scholar
• Rossouw JEea. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297(13):1465-77
   Google Scholar
• Toh S, Hernandez-Diaz S, Logan R, Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010;152(4):211-7
   Google Scholar
• Bonds DE, Lasser N, Qi L, The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia 2006;49(3):459-68
   Google Scholar
• Margolis KL, Bonds DE, Rodabough RJ, Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47(7):1175-87
   PubMed Web of Science ®Google Scholar
• Chu MC, Cosper P, Nakhuda GS, Lobo RA. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 2006;86(6):1669-75
   PubMed Web of Science ®Google Scholar
• Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009;12(5):445-53
   Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies:results from the E3N cohort study. Breast cancer Res Treat 2008;107:103-11
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration and progestogens: the ESTHER Study. Circulation 2007;115:840-5
   PubMed Web of Science ®Google Scholar
• Davison SL, Bell R, Donath S, Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90(7):3847-53
   Google Scholar
• Burger HG, Dudley EC, Cui J, A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85(8):2832-8
   Google Scholar
• Somboonporn W, Davis SR, Seif MW Testosterone for peri and postmenopausal women. Cochrane Database Syst Rev 2005;19(4):CD004509
   Google Scholar
• Buster JE, Kingsberg SA, Aguirre O, Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105(5):944
   Google Scholar
• Braunstein GD, Shifren J, Simon J, Testosterone patches for the treatment of low sexual desire in surgically menopausal women [abstract 60]. In: Program and abstracts of the 14th annual meeting of The North American Menopause Society, 17 – 20 September 2003; Miami Beach, FL
   Google Scholar
• Davis SR, van der Mooren MJ, van Lunsen RHW, The Efficacy and Safety of a Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women: a Randomized, Placebo-Controlled Trial. Menopause. 2006;13(3):387-96
   Google Scholar
• Shifren J, Davis SR, Moreau M, Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause 2006;13(5):770-9
   PubMed Web of Science ®Google Scholar
• Procter and Gamble Pharmaceuticals I. Intrinsa® (testosterone transdermal system) NDA No. 21-769. In: Drugs ACfRH, ed. Vol. 2006. US Food and Drug Administration, Washington DC; 2004
   Google Scholar
• Somboonporn W, Davis S. Testosterone and the breast: therapeutic implications for women. Endocr Rev 2004;25:374-88
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000;3(2):101-5
   Google Scholar
• Zhou J, Ng S, Adesanya-Famuiya O, Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000;14(12):1725-30
   Google Scholar
• Dimitrakakis C, Zhou J, Bondy CA. A physiological role for testosterone in limiting primate mammary epithelial proliferation in vivo. Climacteric 2002;5(S1):137
   Google Scholar
• Hofling M, Hirschberg AL, Skoog L, Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007;14(2):159-62
   Google Scholar
• Bell RJ, Davison SL, Papalia MA, Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause 2007;14(4):630-8
   Google Scholar
• Kloosterboer H. Tibolone: a steroid with tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-8
   PubMed Web of Science ®Google Scholar
• Egarter C, Huber J, Leikermoser R, Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996;23(1):55-62
   Google Scholar
• Archer DF, Hendrix S, Ferenczy A, Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. Fertil Steril 2007;88(4):866-78
   Google Scholar
• Doren M, Rubig A, Coelingh Bennink, Holzgreve H. Differential effects of the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75(3):554-9
   Google Scholar
• Archer DF, Hendrix S, Gallagher JC, Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911-18
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359(7):697-708
   Google Scholar
• Archer DF, Hendrix S, Gallagher JC, Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92(3):911-18
   Google Scholar
• Nijland E, Weijmar Schultz, Nathorst-Boos WCM, Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5(3):646-56
   Google Scholar
• Lokkegaard E, Andreasen AH, Jacobsen RK, Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29(21):2660-8
   PubMed Web of Science ®Google Scholar
• Nijland EA, Nathorst-Boos J, Palacios S, Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric 2009;12(2):114-21
   Google Scholar
• Labrie F, Belanger A, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997;82(8):2403-9
   Google Scholar
• Zumoff B, Rosenfeld RS, Strain GW. Sex differences in the 24 hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults. J Clin Endocrinol Metab 1980;51:330-334
   PubMed Web of Science ®Google Scholar
• Davison SL, Bell R, Donath S, Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90(7):3847-53
   Google Scholar
• Baulieu E, Thomas G, Legrain S, Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci 2000;97(8):4279-84
   PubMed Web of Science ®Google Scholar
• Kritz-Silverstein D, von Muhlen D, Laughlin GA, Bettencourt R. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. J Am Geriatr Soc 2008;56(7):1292-8
   Google Scholar
• Nair KS, Rizza RA, O'Brien P, DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355(16):1647-59
   Google Scholar
• Panjari M, Bell RJ, Jane F, The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas 2009;63(3):240-5
   Google Scholar
• Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and well-being. Hum Reprod Update 2007;13(3):239-48
   Google Scholar
• Nedrow A, Miller J, Walker M, Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006;166(14):1453-65
   Google Scholar
• Buijs C, Mom CH, Willemse PH, Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009;115(3):573-80
   Google Scholar
• Pandya KJ, Morrow GR, Roscoe JA, Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366(9488):818-24
   PubMedGoogle Scholar
• Reddy S, Warner H, Guttuso T, Gabapentin, Estrogen, and Placebo for Treating Hot Flushes. Obstet Gynecol 2006;108:41-48
   PubMed Web of Science ®Google Scholar
• Reddy KS. Cardiovascular disease in non-western countries. N Eng J Med 2004;350:2438
   PubMed Web of Science ®Google Scholar
• Evans ML, Pritts E, Vittinghoff E, Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105(1):161-6
   Google Scholar
• Loprinzi C, Kugler J, Sloan J, Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356(9247):2059-64
   Google Scholar
• Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289(21):2827-34
   Google Scholar
• Williams VS, Baldwin DS, Hogue SL, Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry 2006;67(2):204-10
   Google Scholar
• Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl 3):10-21
   PubMed Web of Science ®Google Scholar
• Davis SR, Dalais FS, Simpson ER, Murkies AL. Phytoestrogens in Health and Disease. Recent Prog Horm Res 1999;54:185
   PubMedGoogle Scholar
• Lethaby A, Brown J, Marjoribanks J, Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007(4):CD001395
   Google Scholar
• Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104(4):824-36
   Google Scholar
• Lontos S, Jones RM, Angus PW, Gow PJ. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2003;179:390-1
   PubMed Web of Science ®Google Scholar
• Chow EC, Teo M, Ring JA, Chen JW. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust 2008;188(7):420-2
   Google Scholar
• Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with ‘bioidentical’ hormone replacement therapy. Med J Aust 2007;187(4):244-5
   Google Scholar
• Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14(2):168-82
   PubMed Web of Science ®Google Scholar
• Pike AC, Brzozowski AM, Hubbard RE, Structure of the ligand- binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999;18(17):4608
   PubMedGoogle Scholar
• Ettinger B, Black D, Mitlak B, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-45
   PubMed Web of Science ®Google Scholar
• Bevers TB. The STAR Trial: Evidence for Raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 2007;5(8):817-22
   Google Scholar
• Barrett-Connor E, Cox DA, Song J, Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med 2009;122(8):754-61
   Google Scholar
• Davis SR, O'Neill SM, Eden J, Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study. Menopause 2004;11(2):167-75
   Google Scholar
• Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause 2010. [Epub ahead of print]
   Google Scholar
• Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13:132-40
   PubMed Web of Science ®Google Scholar